Efficacy and safety of PCSK9 inhibition in cardiovascular disease: A meta-analysis of 45 randomized controlled trials

BACKGROUND: Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascul...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Qiang, Li, Xuan, Sun, Qingjiao, Wang, Zhengzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2022
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273234/
https://www.ncbi.nlm.nih.gov/pubmed/34581425
http://dx.doi.org/10.5603/CJ.a2021.0110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273234/
https://www.ncbi.nlm.nih.gov/pubmed/34581425
http://dx.doi.org/10.5603/CJ.a2021.0110

Ejemplares similares